Bausch Health Companies Inc
TSX:BHC

Watchlist Manager
Bausch Health Companies Inc Logo
Bausch Health Companies Inc
TSX:BHC
Watchlist
Price: 10.51 CAD -2.59%
Market Cap: 3.9B CAD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one BHC stock under the Base Case scenario is hidden CAD. Compared to the current market price of 10.51 CAD, Bausch Health Companies Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BHC Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

0.3
P/S
P/S
Price to Sales
0.3
vs History
76
vs Industry
89
Median 3Y
0.3
Median 5Y
0.4
Industry
2.7
Forward
0.3
More Details
28.6
P/E
P/E
Price to Earnings
28.6
vs History
4
vs Industry
Median 3Y
-7.1
Median 5Y
-8.3
Industry
22.2
Forward
1.7
More Details
1.9
P/OCF
P/OCF
Price to OCF
1.9
vs History
63
vs Industry
52
Median 3Y
1.7
Median 5Y
2.7
Industry
17.2
More Details
2.1
P/FCFE
P/FCFE
Price to FCFE
2.1
vs History
38
vs Industry
36
Median 3Y
1.1
Median 5Y
1.2
Industry
23.7
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-3.3
Industry
2.3
More Details
2.2
EV/S
EV/S
Enterprise Value to Sales
2.2
vs History
90
vs Industry
48
Median 3Y
2.7
Median 5Y
2.8
Industry
2.8
Forward
2.2
More Details
3.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.2
vs History
90
vs Industry
60
Median 3Y
3.8
Median 5Y
3.9
Industry
5.6
More Details
7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7
vs History
88
vs Industry
42
Median 3Y
8.1
Median 5Y
8.4
Industry
13.3
Forward
6.3
More Details
11.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.7
vs History
90
vs Industry
35
Median 3Y
15
Median 5Y
16.2
Industry
16.5
Forward
6.8
More Details
14.6
EV/OCF
EV/OCF
Enterprise Value to OCF
14.6
vs History
66
vs Industry
32
Median 3Y
14.3
Median 5Y
21.3
Industry
15.6
More Details
19.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
19.9
vs History
65
vs Industry
25
Median 3Y
19.6
Median 5Y
26.7
Industry
17.9
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
85
vs Industry
63
Median 3Y
0.9
Median 5Y
0.9
Industry
2
More Details

Multiples Across Competitors

BHC Competitors Multiples
Bausch Health Companies Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Bausch Health Companies Inc
TSX:BHC
4B CAD 0.3 28.6 7 11.7
US
Eli Lilly and Co
NYSE:LLY
665.8B USD 12.5 48.2 28.6 31
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
427.7B USD 4.7 18.9 14.4 18.9
CH
Roche Holding AG
SIX:ROG
208B CHF 3.4 25.1 9.4 11
UK
AstraZeneca PLC
LSE:AZN
185B GBP 4.4 30.1 113.6 169.8
CH
Novartis AG
SIX:NOVN
197.8B CHF 4.5 17.9 10.8 14.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.9 13.9 10.2 11.3
US
Merck & Co Inc
NYSE:MRK
213.7B USD 3.4 13 8.4 10
IE
Endo International PLC
LSE:0Y5F
183.4B USD 79.1 -62.7 291.8 731.8
US
Pfizer Inc
NYSE:PFE
143.9B USD 2.3 13.4 7.5 10.3
P/E Multiple
Earnings Growth PEG
CA
Bausch Health Companies Inc
TSX:BHC
Average P/E: 23.2
28.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.2
49%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.9
27%
0.7
CH
Roche Holding AG
SIX:ROG
25.1
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
30.1
36%
0.8
CH
Novartis AG
SIX:NOVN
17.9
16%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
18%
0.8
US
Merck & Co Inc
NYSE:MRK
13
17%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -62.7 N/A N/A
US
Pfizer Inc
NYSE:PFE
13.4
30%
0.4
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Bausch Health Companies Inc
TSX:BHC
Average EV/EBITDA: 395.3
7
9%
0.8
US
Eli Lilly and Co
NYSE:LLY
28.6
30%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.4
8%
1.8
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
113.6
10%
11.4
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
13%
0.8
US
Merck & Co Inc
NYSE:MRK
8.4
7%
1.2
IE
E
Endo International PLC
LSE:0Y5F
291.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Bausch Health Companies Inc
TSX:BHC
Average EV/EBIT: 1 702
11.7
25%
0.5
US
Eli Lilly and Co
NYSE:LLY
31
33%
0.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
18.9
14%
1.3
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
UK
AstraZeneca PLC
LSE:AZN
169.8
23%
7.4
CH
Novartis AG
SIX:NOVN
14.3
10%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
731.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
9%
1.1

See Also

Summary
BHC intrinsic value, competitors valuation, and company profile.
DCF Valuation
BHC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BHC stock valuation using valuation multiples.
Wall Street Estimates
BHC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BHC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 276,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.